echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > "Weekly Jun" 2020 first half of the exposure season, 200 pharmaceutical companies half-yearly reports focused on the publication;

    "Weekly Jun" 2020 first half of the exposure season, 200 pharmaceutical companies half-yearly reports focused on the publication;

    • Last Update: 2020-09-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Before August 30, more than 200 pharmaceutical companies H1 newspaper will be announced to complete, who earns who loses at a glance.
    . This week's point of view 1. Semi-annual report shows that the CXO industry in the epidemic continued to be high business climate 2. Fosun Pharma 2020 semi-annual report: revenue of 14.028 billion yuan net profit of 1.715 billion yuan 3. East Sunshine core product sales fell seriously; Enterprise information Kanglong into, pharmaceutical stone technology 2020 mid-year report released in the outbreak of the CXO industry continued to be high business climate on August 26, Kanglong into and pharmaceutical stone technology has released the 2020 mid-year report.
    's first-half net profit rose 196.89 percent and gross margin increased 4.34 percentage points.
    in most industries by the new crown outbreak serious situation, the first half of Kanglong into the performance is still very bright.
    the report showed that during the reporting period, the company achieved revenue of RMB2,193 million, up 34.01% YoY;
    company's profits to achieve high growth, the overall profitability further improved.
    second quarter revenue growth rate of more than 100%, the overall gross margin continued to decline.
    2020 mid-year report, the company achieved revenue of RMB459 million in the first half of this year, up 58.17% YoY; In the
    quarter, the company's Q2 revenue, attributable net profit and non-attributed net profit growth rate of 108.46 percent, 65.35 percent and 66.78 percent, respectively, the performance has a clear accelerated growth trend.
    is the same as Kanglong into the same, Q1 quarter affected by the outbreak, the company's performance growth slowed, and in Q2 quarter, benefit from the company's kilogram-class orders and technical services revenue growth, performance fully restored to a high-speed growth state.
    May be due to the outbreak, the CXO industry continued to maintain a high business climate, new drug research and development and its returns there is a high degree of uncertainty, and CXO as a pharmaceutical research and development industry "water seller", in the context of continuous improvement in research and development investment, the industry as a whole to maintain a high level of prosperity.
    even under the outbreak, the CXO sector has been less affected, continuing to maintain a high degree of prosperity and achieving steady growth in performance.
    recently disclosed CRO/CDMO companies, the performance of enterprises in this sector in the first half of this year remains strong.
    although Q1 was affected by the outbreak led to a phased slowdown in growth, but Q2 quarter has quickly returned to a high-speed growth state, the industry is expected to continue to maintain high-speed growth in the second half of this year.
    same time, sharing the growth dividend of the global CXO industry, industry orders continue to shift to China, coupled with the impact of the epidemic, industrial transfer is more obvious, the follow-up overseas industrial transfer is expected to accelerate.
    Shi Pharmaceuticals invested 1,452 million yuan in research and development in the first half of the year, sales of albumin yew alcohol increased by 70.9% On August 26, Shi pharmaceutical group announced its first-half 2020 results, with revenue of 12.59 billion yuan, up 12.6% YoY;
    research and development expenses amounted to 1,452 million yuan, an increase of 54.2% YoY, accounting for about 14.2% of the revenue of the pharmaceutical business.
    , the revenue of the pharmaceutical business was RMB10,231 million, up 16.7% YoY, while the revenue of the vitamin C (API) business was RMB1,005 million, down 13.2% YoY, and the revenue of the antibiotic (API) business was RMB478 million, down 10.0% YoY.
    Deqi Pharmaceuticals filed an IPO application on the Hong Kong Stock Exchange to promote 12 new drug development on August 26, the HKEx website announced that Antengene has formally submitted an IPO application on the Hong Kong Stock Exchange, the co-sponsors are Goldman Sachs, J.P. Morgan.
    the prospectus, the company is a biotech company as defined in Chapter 18A of the Listing Rules.
    fund-raising will be used primarily to promote clinical development of products in the research pipeline, where oral selective nuclear output protein inhibitors (SINE) ATG-010 are conducting two Phase 2 registered clinical trials in China.
    current 6 clinical stage candidates are: ATG-010, ATG016, ATG-527, ATG-008, ATG-019 and ATG-017, 6 preclinical Candidate drugs ATG-101, ATG-018, ATG-012, ATG-022, ATG-031 and ATG-027 can be said to have great prospects for the future, to a large extent, is undoubtedly the core competitiveness of the company.
    Compaq's first-half sales fell 24% On August 25, Kanghong Pharmaceuticals announced its first-half 2020 results, reporting revenue of RMB1,393 million, down 8.26% YoY, and realizing net profit attributable to shareholders of listed companies of RMB335 million, down 1.68% YoY.
    , sales of biological products were RMB423 million, down 24.51 percent year-on-year.
    most interesting aspect of biologic drugs, Compaqsip eye injection (commodity name: Lang Mu) is conducting international multi-center Phase III clinical research.
    has been approved for three adaptive disorders (wet age-related macular degeneration (nAMD), treatment of diabetic macular edema (DME) caused by vision damage, secondary to pathological myopia vascular new blood vessels caused by vision impairment (pmCNV), retinal venous obstruction (RVO) is currently in China's clinical III.phase, related research is progressing as planned.
    can say that, to a large extent, Kanghong Pharmaceuticals' biopharmacerie hopes on "Compaxip", look forward to the early launch of products to bring considerable revenue.
    on August 24th, Beijing New Pharmaceuticals released its 2020H1 results report, with first-half sales revenue of RMB1,641 million, down 11.73 percent year-on-year, including the second quarter. Sales revenue was RMB847 million, up 6.68 percent from the first quarter, and net profit attributable to listed companies in the first half was RMB225 million, down 30.95 percent year-on-year, of which net profit was RMB129 million in the second quarter, up 35.13 percent from the first quarter.
    semi-annual report shows that beijing-new pharmaceutical industry's first-half results fell year-on-year mainly due to: (1) the country's second batch of collection and promotion, related preparation products and API products have significantly decreased in market prices, sales revenue decreased year-on-year.
    (2) the outbreak and spread of the new crown epidemic, its resumption of production, some products sales business has caused a certain negative impact.
    specifically reflected in the finished products, in the first half of 2020 to achieve overall sales revenue of 1.002 billion yuan, down 8% YoY, the spiritual nerve sector to achieve sales revenue of 194 million yuan, up 55% YoY, continue to maintain a rapid growth trend; 63 million yuan, down 21% YoY, mainly due to the collection and price reduction of Ruishu, Xinval, digestive sales revenue of 177 million yuan, down 16% YoY, mainly affected by the new crown outbreak, hospital outpatients abnormal, sales did not meet expectations.
    Pharma 2020 Semi-Annual Report: Revenue 14.028 billion net profit 1.715 billion yuan August 25, Fosun Pharma released its 2020 Semi-Annual Report, the first half of the operating income of 1,40 2,816.46 million yuan, down slightly 1.02% from the same period in 2019, and net profit of 171,471.02 million yuan, up 13.10% from the same period in 2019.
    Profit growth mainly came from: (1) the contribution of new coronavirus nucleic acid testing kits, negative pressure ambulances and ventilators and other anti-epidemic products; Production scale (2,000L) was approved after the rapid increase in sales, the first half of the revenue of 224 million yuan, june revenue exceeded 100 million yuan;
    same time, in the research and development of small molecule drugs, independent research and development and product introduction of two ways in parallel, with small molecules innovative drugs have entered the clinical stage, research and development investment is also growing steadily.
    increase in research and development investment during the reporting period was mainly due to the Group's increased investment in research and development of biological drugs, small molecule innovative drugs and imported innovative drugs, as well as increased investment in innovative incubation platforms.
    2020H1 Results: Revenue of 1.207 billion yuan research and development investment of 238 million yuan August 24, Gan Li Pharmaceuticals released the 2020 semi-annual report, operating income of 1.207 billion yuan, an increase of 25.93 percent;
    , domestic sales revenue increased by 29.55 percent year-on-year, while foreign sales revenue increased by 279.85 percent year-on-year with the increase of foreign customers.
    In the first half of 2020, Ganli Pharmaceutical Mendong insulin was approved for listing by the State Drug Administration, the new drug GLR2007 in the United States Phase I clinical trial patients also officially started, 3 main products: insulin glaccerin, insulin and mendon insulin in Europe and the United States of America, the key Phase I clinical successfully completed, and the clinical phase III.
    development team and European and American partners Sanders fully cooperate in preparation for the Declaration of Europe and the United States, but also made substantial progress.
    in research and development, In addition to continuing to develop new diabetes-related product pipelines, Gan Li Pharmaceuticals has also been promoting drug development in other fields, such as oncology, immunotherapy and cell therapy.
    investment in research and development in the first half of this year was 238 million yuan, an increase of 18.03 percent.
    , the investment in cost-based research and development was RMB187 million, an increase of 105.68 percent, and the share of sales revenue increased from 9.50 percent in the same period last year to 15.52 percent in the current period;
    's core products sales fell 32.9% in the first half of the year, Dongsan released its first half 2020 results report, with a turnover of 2,083 million yuan, down 32.3% YoY, and gross profit of 1.730 billion yuan, down 34.0% YoY.
    East Sunshine financial results show that in the first half of the year due to the impact of the new coronavirus outbreak, the mobility of personnel decreased, so its core product Phosphate Ostave sales also fell, to 1,967 million yuan, down 32.9% YoY, accounting for 94.4% of its turnover.
    , the sales of Cowei particles were 1,020.6 million yuan, and the sales of Covey capsules were 946.8 million yuan.
    During the outbreak, in addition to emergency departments and some important departments, other health care workers were urgently dispatched to fever clinics and first-line anti-epidemic areas, the overall flow of hospitals, the number of medical activities, prescriptions have dropped significantly, drug sales have also declined.
    with the domestic epidemic under control, the number of outpatients gradually increased, treatment needs will gradually release, Dongsian expected the future sales will gradually recover.
    government wants $520 billion! Health insurance is about to usher in the history of the "big expansion" of these pharmaceutical companies are most affected! On August 26th, the Health Insurance Bureau issued the Draft for Comments on the Reform of Individual Accounts for Employees' Health Insurance, and the reform of individual accounts for health insurance began to come to an end.
    Among the key content tips: First, the general clinic began to be included in the scope of co-ordination fund payment, the proportion is not less than 50%;
    addition to workers' medical insurance, China also has urban residents' medical insurance and a new rural cooperative medical system (new agricultural joint).
    due to the low amount of contributions, so reimbursement is naturally not comparable to the staff medical insurance.
    reform, this part of the people can also share the employee health insurance account.
    this balances the mood of "young people" regarding the partial transfer of personal account funds to co-ordinated funds, and further activates factors such as the efficiency of the use of personal account balance funds.
    market hot news rose more than 1000%! GEM registration system landed on the first day, pharmaceutical stocks are hot! August 24, the domestic capital market once again ushered in a new change: GEM registration system landed! On the first day, the Shenzhen Stock Exchange GEM reform and pilot registration system of the first batch of 18 new shares collective bell, after the opening of the whole line of new shares skyrocketed.
    new shares of Kantai Medical opened at 55 yuan, the largest increase of more than 2900%, twice triggered a stop, in the last 2 minutes of the stock price fell from 308 yuan to 118 yuan.
    of the 18 new shares rose the most, with a market capitalisation of more than $47.4 billion.
    statistics, the market value of these 18 new shares increased by more than 100 billion yuan.
    in the stock market, Tianshan creature first tasted 20% of the delicious rise and fall.
    And gem caused the capital market, industry level of high concern, the main reason is due to the importance of its changes: 1. GEM to increase new shares do not set the number of days of rise or fall, the first 5 trading days do not set a limit on the rise or fall;
    limit on the daily rise and fall of GEM shares will be relaxed from 10 per cent to 20 per cent.
    all three are new bright spots of the GEM, but also the root of the hot turnover of the board, the same day the transaction has exceeded 48.5 billion yuan, the average increase of 140% throughout the day.
    in the context of the GEM, the market is expected to continue to boom, but at the same time there are still many challenges. More than
    frequently issued documents on the expansion of large hospitals came on August 21, Tianjin Health and Health Commission website published the "Tianjin Health care institutions layout plan (2015-2035) (2019 revision)" (hereinafter referred to as the "Plan"), "Plan" clearly in the next 15 years Tianjin will build 59 new hospitals, including 32 general hospitals, 27 specialized hospitals.
    planning the city's medical and health can accommodate the total.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.